Study of Epratuzumab in Systemic Lupus Erythematosus
Study of Epratuzumab in Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety & efficacy of Epratuzumab with standard
 treatments for patients with SLE.
Inclusion Criteria:

 -  Has SLE by ACR revised criteria (meets <4 criteria);

 -  Has SLE with at least one elevated lupus antibody;

 -  Has new onset of severe lupus disease flare in at least one body or organ system,
 excluding renal or neurologic

 Exclusion Criteria:

 -  Active severe CNS or Renal disease defined by BILAG as Level A

 -  Allergy to murine or human antibodies

 -  Antiphospholid antibodies AND a history of thrombocytopenic events